U.S. Semiconductors Stock News

The market barely flinched on ArcBest’s Q2 release. The stock inched up about 0.4% despite a headline that, on paper, looks far more dramatic than that move suggests. ArcBest posted a Q2 net loss and negative basic earnings per share while still delivering higher revenue and stronger non GAAP operating income. This is a margin story more than a growth story. Freight investors are weighing a reported loss that reflects heavy restructuring and impairment charges against an improving operating...

The market barely flinched on Humana’s earnings, with the stock up just 0.3% around US$366. That muted move sits against a report defined by margin repair rather than headline growth. Quarterly basic earnings per share of US$5.78 and net income of US$694m came alongside a clear message. Management is leaning hard into restoring Medicare Advantage profitability after a year of thinner margins and a large one off loss in the trailing period. For investors, the real story is whether this slow...

United Natural Foods recently reported that its natural product sales grew more than 4% in fiscal 2026, while it rolled out new digital tools, refreshed private-label offerings, and continued heavy investment in modernizing its supply-chain operations. This combination of category growth and technology-driven efficiency initiatives underscores how UNFI is trying to reinforce its role as a key distributor for health-focused retailers and brands. Next, we’ll examine how UNFI’s renewed push...

In the past quarter, Lincoln Electric Holdings, Inc. reported second-quarter 2026 sales of US$1,219.66 million and net income of US$158.52 million, with diluted earnings per share from continuing operations of US$2.88, and affirmed a quarterly dividend of US$0.79 per share payable on October 15, 2026. Beyond the headline growth, Lincoln Electric’s ability to expand earnings while keeping operating margins stable suggests cost discipline is supporting its higher revenue base. We’ll now...

Watsco came into this earnings print with the stock drifting lower for months and another 2.9% slide today, despite posting one of its seasonally strongest quarters. The market is leaning away from the long term HVAC distribution story just as the company reported US$2.1b in Q2 revenue and US$4.28 in basic earnings per share. The headline is not growth at any cost. Investors are focusing on margins. Gross margin landed at 27.5% and trailing net margin sits at 6.1%, both a step down from a...

New Oriental Education & Technology Group saw its stock slip 3.4% to US$56.58, even though the headline number pointed in the opposite emotional direction for many investors. Revenue in the latest quarter reached US$1,529.5m and non GAAP operating income came in at US$110m, which management framed as part of a broader profitability push. The tension today sits squarely between a premium P/E of 18.9x and a business still delivering earnings growth and higher net profit margins. The price fall...

Eastman Chemical Company has reported its second-quarter 2026 results, with sales of US$2,513 million and net income of US$183 million, both higher than the same period a year earlier. While quarterly earnings per share increased year over year, the six-month figures show lower net income and EPS compared with the prior-year period, highlighting a mixed profitability trend beneath the headline growth. We’ll now examine how this mix of higher quarterly sales and income but softer year-to-date...

Enterprise Products Partners has delivered a 146.4% total return over the past five years, yet the latest valuation checks send a more measured signal about how much upside might still be left in the current price of US$38.12. A 146.4% return over five years points to a stock that has already rewarded patient holders, which raises the bar for any new valuation upside. Future cash flow resilience from its midstream infrastructure can support current pricing, while any sustained pressure on...

In July 2026, Celcuity announced that its drug REVTORPYK (gedatolisib) received FDA approval and NCCN Category 1 preferred guideline status for use with fulvestrant, with or without palbociclib, in adults with HR+/HER2- locally advanced or metastatic breast cancer without a PIK3CA mutation after progression on endocrine therapy. A key differentiator is that REVTORPYK is the only FDA-approved therapy targeting all class I PI3K isoforms and both mTORC1 and mTORC2 complexes, supported by...

Range Resources Corporation recently reported its second-quarter 2026 results, with revenue of US$833.57 million and net income of US$195.32 million, alongside an update that it repurchased 2,000,000 shares for US$78.35 million, completing a total buyback of 35,915,000 shares under its 2019 authorization. While quarterly revenue and earnings were lower than a year earlier, the company’s stronger first-half results and completion of a multi-year buyback program highlight how capital returns...

Solstice Advanced Materials stock has given investors a sharp correction in the past month, yet the current market-multiple view still leans on the expensive side and the broader valuation checks only offer a mixed verdict rather than a clear bargain. The share price is down 35.2% over the past month, which pressures confidence in how much investors are willing to pay for the stock right now. The planned acquisition of Element Solutions may support expectations for a larger advanced...

KBR (NYSE:KBR) has named its planned independent Mission Technology Solutions spin-off "Trinzic." The company also announced executive designations for Trinzic as part of the separation process. This move marks a further step toward formally separating the Mission Technology Solutions business from KBR. KBR operates across government services and technology-focused engineering, with Mission Technology Solutions playing a central role in its defense and intelligence-facing work. The formal...

SELLAS Life Sciences Group (SLS) is back in focus as investors watch for the final analysis of its Phase 3 REGAL trial in acute myeloid leukemia, with the pivotal readout reportedly close. See our latest analysis for SELLAS Life Sciences Group. At a share price of $10.29, SELLAS Life Sciences Group has seen a very large 1 year total shareholder return. The 90 day share price return of 108.72% contrasts with a 30 day share price decline of 30.28%, suggesting momentum has cooled as investors...

Rithm Capital (NYSE:RITM) is weighing a potential shift from its current real estate investment trust structure to a traditional C corporation, according to recent management commentary. The company is also working to expand its third party asset management platform and grow fee based revenue streams. Rithm Capital enters this decision point with shares recently trading around $9.87. The stock is up 9.9% over the past week and 5.1% over the past month, while returns year to date and over...

Hercules Capital stock is coming off a solid 5 year return, yet current checks suggest the market price may still sit below what its fundamentals imply. At the last close of US$15.94, both the intrinsic value estimate from the Excess Returns model and the earnings multiple view point to a market that may be underpricing the company. Hercules Capital has returned 60.3% over the past 5 years, which puts recent short term weakness into a longer term context of gains. Future lending growth and...

TeraWulf stock has delivered a very large 3 year gain, yet its current valuation checks do not flag it as a clear bargain. After a sharp run and recent pullback, investors are left weighing strong past returns against a weak overall value score. Over the past 3 years, TeraWulf has returned about 5.8x, which puts extra focus on whether today’s price still leaves much room for error. Recent attention around AI data center financing and sector deals may support growth expectations for TeraWulf,...

Heavy spending on AI by Big Tech is creating a clear split in market opinion. Investors are rewarding companies like Microsoft and Amazon that can point to real AI revenue, while punishing those with vague AI ambitions and weak free cash flow such as Alphabet and Meta. At the same time, consumer appetite for new tech and AI features from companies like Apple and Google remains strong. This article looks at 3 Consumer Technology Innovators that are exposed to this AI news cycle and may offer...

Cybersecurity tests that allowed Anthropic’s AI models to breach external firms, along with comparable issues at OpenAI, are a sharp reminder that AI risk is not just technical. It is legal, compliance and reputational. As regulators respond with tighter oversight and higher expectations, spending on legal and compliance services could shift in meaningful ways. For investors, that can mean new potential opportunity or fresh risk depending on how companies sit within this regulatory trend...

Eagle Materials stock slipped about 2.1% today, yet the earnings story is more nuanced than that headline move suggests. Coming into the print, shares had already eased over the past month, so expectations were not stretched. Against that backdrop, the company posted record Q1 fiscal 2027 revenue of US$651 million and basic earnings per share of US$3.30, while still absorbing higher freight costs and a US$6 million hit from downtime at its Mountain cement facility. The market is reacting to...

Morgan Stanley Investment Management recently launched two new Ethereum (MSSE) and Solana (MSOL) exchange-traded products on NYSE Arca that pass staking rewards directly to investors, while the firm also issued US$50.00 million of 4.500% senior unsecured notes due September 28, 2027, and expanded its leadership by hiring Emma Taylor to co-lead global internet banking. This move positions Morgan Stanley among the first major U.S. banks to package yield-bearing crypto exposure into regulated,...

Arista Networks stock has delivered a very strong multi year return, yet the latest valuation checks suggest the shares no longer stand out as a clear bargain. The intrinsic value estimate from a Discounted Cash Flow (DCF) model sits close to the current price, while market multiples lean rich. Arista Networks has returned about 6x over the past five years, which sets a high bar for any further upside to be justified by fundamentals. The launch of Arista's AI driven Zero Trust Branch...

Relay Therapeutics, a clinical-stage precision medicine company, recently announced it will report its second quarter 2026 results and corporate highlights on 6 August 2026, with investors watching closely for updates on its lead asset zovegalisib and other pipeline programs. Analysts have turned more optimistic ahead of this report, pointing to the potential for an earnings beat alongside progress in the company’s oncology and genetic disease trials as key areas of focus. With attention...

China’s latest manufacturing data has sent a clear signal. The official PMI slipped to 49.2 in July, which points to weaker factory activity, softer exports to the U.S., and pressure on retail sales and jobs. At the same time, Chinese policymakers are talking up extra fiscal support and pro growth measures. For U.S. investors, this mix of softer demand abroad and potential policy support at home and overseas can change how industrial and manufacturing stocks are priced. This article looks at...

Southern Michigan Bancorp stock sat at $31.88 coming into the Q2 release, with a flat month behind it and a solid 90 day climb, and the results now force investors to decide whether the calm was complacency. The headline is simple. Earnings stayed firm with basic earnings per share at $0.66 and trailing 12 month earnings quality described as high, while the net profit margin eased to 21.3%. The question now is whether today’s price reaction reflects that mild squeeze in profitability or...